England on Track to Eliminate Hepatitis C Ahead of WHO 2030 Target Following NHS Drug Deal and Targeted Screening
核心洞察
England is poised to eliminate hepatitis C (搜索) as a public health threat ahead of the WHO's 2030 goal, driven by a landmark £1 billion NHS drug procurement agreement.
Over 100,000 people have received curative direct-acting antiviral (搜索) treatment since 2015, with hepatitis C (搜索)-related deaths falling by more than 35%.
The NHS deployed mobile testing vans, emergency department opt-out screening, and prison programs to reach marginalized populations including people experiencing homelessness and those who inject drugs.
England is on track to eliminate hepatitis C (搜索) as a public health threat, outpacing the World Health Organization's 2030 target through an aggressive combination of widespread antiviral access, innovative commercial contracting, and proactive community-based screening. NHS England (搜索) announced that over 100,000 people have successfully accessed life-saving treatment since 2015, marking what public health officials describe as a major breakthrough in the fight against a virus that can lead to liver failure and liver cancer.
The results have been striking: deaths from hepatitis C (搜索)-related liver disease and cancer have dropped by more than 35% over the last decade, and the need for hepatitis C-driven liver transplants has plummeted.
A Landmark Drug Deal That Removed Financial Barriers
Central to England's success is a pioneering £1 billion commercial agreement between the NHS and pharmaceutical companies. Under this fixed-price "population-level" contract, the NHS secured unlimited supplies of modern direct-acting antiviral (搜索) (DAA) tablets, effectively eliminating the financial barriers that often constrain treatment scale-up in public health systems.
These oral antiviral medications can cure over 95% of hepatitis C (搜索) cases within a few weeks, usually with minimal side effects. The drugs represent a transformative advance over older interferon-based regimens, which were less effective, required longer treatment durations, and carried significant toxicity burdens.
Reaching the Hardest-to-Reach Populations
Rather than relying solely on patients to present for care, NHS England (搜索) adopted an assertive outreach strategy. Mobile testing vans, emergency department opt-out testing programs, prison screening initiatives, and peer-led support networks were deployed to find and treat marginalized or high-risk groups—including people experiencing homelessness and those who use injectable drugs.
This proactive approach addresses a core challenge in hepatitis C (搜索) elimination: many individuals with chronic infection remain asymptomatic for years and may not engage with traditional healthcare settings. Common symptoms, when they do appear, include jaundice, severe fatigue, abdominal pain, loss of appetite, nausea, dark-colored urine, pale stools, and flu-like signs such as low-grade fever and joint pain.
Europe's Uneven Progress Highlights the Challenge
England's trajectory stands in contrast to broader European trends. According to new data from the European Centre for Disease Prevention and Control (搜索) (ECDC), the region as a whole is set to miss the 2030 elimination target due to uneven implementation of key measures. An estimated five million people in the EU/EEA are living with chronic hepatitis B (搜索) or C, and almost 60,000 people die each year from liver disease linked to these infections.
"No one should die from a disease that is preventable, diagnosable and treatable," said Bruno Ciancio of ECDC. "Yet millions of Europeans are living with chronic hepatitis B (搜索) or C infections – often without knowing it – which can lead to severe long-term consequences such as liver failure or liver cancer."
The ECDC data reveal persistent gaps: only nine out of 25 EU/EEA countries have reached the WHO target of fully vaccinating 95% of children against hepatitis B (搜索), and only seven countries meet the WHO target for distribution of sterile injection equipment for people who inject drugs—a population that accounts for most hepatitis C (搜索) cases with a known transmission route.
No Vaccine, But a Cure
Currently, there is no vaccine for hepatitis C (搜索), though vaccines are available to protect against hepatitis A and hepatitis B (搜索). The absence of a prophylactic vaccine makes the curative potential of DAAs all the more critical to elimination efforts. ECDC and the European Union Drugs Agency have outlined key interventions for people who inject drugs and developed an online toolkit to support elimination efforts in prisons—settings where improved healthcare could substantially reduce transmission.
England's experience demonstrates that with sufficient political will, innovative financing, and targeted outreach, elimination of hepatitis C (搜索) as a public health threat is achievable well ahead of global timelines.